CORDIS
EU research results

CORDIS

English EN
Targeted delivery of nanomedicine

Targeted delivery of nanomedicine

Objective

MEDITRANS will develop systems for targeted delivery of nanomedicines, which will be broadly applicable to disease. The focus is on chronic inflammatory disorders and cancer. Such industrially developed targeted products will improve therapy and in vivo visualisation of drug delivery/release processes.

Nanocarriers (nanoparticles, nanotubes, fullerenes), endowed with high targeting capabilities, will be designed in parallel with MRI probes that report on localisation of the targeted nanoparticulates, specific bio-markers, and the drug release process (MRI-guided drug delivery).

For reproducible behaviour in vivo, these nanomedicines containing drug payloads (e.g. pDNA, siRNA, small molecular weight agents) will have their physicochemical/stability properties characterised. 'Smart' delivery systems, tested in vitro, able to recognise the target, and to cross-relevant biological barriers, will be investigated for their responsiveness to the microenvironment of the target site (e.g. local pH).

Control of drug re lease, triggered by external physical means (e.g. temperature, light, magnetism, ultrasound) or by local stimuli within the pathological site (e.g. pH, enzymatic activity) will be investigated in vitro. Ways to direct the intracellular trafficking of nanocarriers, to achieve improved interaction with the intracellular target location, will be investigated.

In vivo applicability will be evaluated in clinically relevant models of disease. Toxicology aspects, industrial scale-up feasibility, long term stability, and feasibility to prepare clinical grade material will be covered.

Dissemination, training and exploitation will be done. MEDITRANS, duration 4 years, is a timely, interdisciplinary IP at the forefront of targeted nanomedicine, with a budget of 16.1M Euro, a grant of 11M Euro (68%), and 1581.75 person-months effort.

The 30 partners (12 European countries) are from industry (8), SMEs (5), universities (11), and research institutes (6).

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITEIT UTRECHT

Address

Heidelberglaan 8
80125 Utrecht

Netherlands

Administrative Contact

Gert STORM (Prof.)

Participants (32)

Sort alphabetically

Expand all

COMMISSARIAT A L'ENERGIE ATOMIQUE

France

STICHTING BIOMADE TECHNOLOGY

Netherlands

MAGFORCE NANOTECHNOLOGIES AG

Germany

CHARITE UNIVERSITATSMEDIZIN BERLIN

Germany

STICHTING VOOR FUNDAMENTEEL ONDERZOEK DER MATERIE - FOM

Netherlands

PCI BIOTECH AS

Norway

UNIVERSITEIT GENT

Belgium

UNIWERSYTET LÓDZKI

Poland

N. V. ORGANON

Netherlands

TECHNISCHE UNIVERSITEIT EINDHOVEN

Netherlands

MOLECULAR PROFILES LTD

United Kingdom

UNIVERSITÄT DES SAARLANDES

Germany

BAYER SCHERING PHARMA AG

Germany

ACROSS BARRIERS GMBH

Germany

BRACCO IMAGING SPA

Italy

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

WEIZMANN INSTITUTE OF SCIENCE

Israel

CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

Spain

GUERBET S.A.

France

PHILIPS TECHNOLOGIE GMBH FORSCHUNGSLABORATORIEN

Germany

INTEGRATED DNA TECHNOLOGIES BVBA

Belgium

UNIVERSIDAD NACIONAL DE EDUCACION A DISTANCIA

Spain

INFUTURIA GROUP AG

Switzerland

COPENHAGEN UNIVERSITY

Denmark

RIJKSUNIVERSITEIT GRONINGEN

Netherlands

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

MERCK-SERONO SA

Switzerland

CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPMENT

Switzerland

ISTITUTO DI RICERCHE BIOMEDICHE ANTOINE MARXER RBM S.P.A.

Italy

PHILIPPS-UNIVERSITÄT MARBURG

Germany

PHILIPS ELECTRONICS NEDERLAND B.V.

Netherlands

UNIVERSITÀ DEGLI STUDI DI TORINO

Italy

Project information

Grant agreement ID: 26668

  • Start date

    1 January 2007

  • End date

    31 March 2011

Funded under:

FP6-NMP

  • Overall budget:

    € 14 839 172

  • EU contribution

    € 10 728 701

Coordinated by:

UNIVERSITEIT UTRECHT

Netherlands